文献速递胸部肿瘤

利用共价抑制剂创建可被免疫治疗靶向的MHC限制性新抗原

Creating MHC-Restricted Neoantigens with Covalent Inhibitors That Can Be Targeted by Immune Therapy.
PubMed 文献 · Cancer Discov · 2023-01-01

该研究建立平台技术,利用共价抑制剂产生的半抗原-肽 conjugate 创建选择性标记癌细胞的新抗原;基于FDA批准的索托拉西布和奥希替尼开发「HapImmune」抗体,结合药物-肽 conjugate/MHC复合物而非游离药物;双特异性T细胞衔接器在索托拉西布处理下选择性杀伤耐药肺癌细胞,对HLA-A*02和A*03/11超型的KRASG12C突变细胞均有效。

要点

  • 共价抑制剂产生的半抗原-肽可作为新抗原呈递于MHC。
  • HapImmune抗体结合药物-肽/MHC复合物,不结合游离药物。
  • 双特异性T细胞衔接器对KRASG12C突变细胞有选择性杀伤作用。

核心结论

  • 该策略通过设计创建可靶向的新抗原,将靶向治疗与免疫治疗统一。

研究设计与样本

  • 临床前平台技术研究,利用FDA批准的共价抑制剂索托拉西布和奥希替尼开发HapImmune抗体及双特异性T细胞衔接器。

主要发现

  • HapImmune抗体结合药物-肽 conjugate/MHC复合物,不结合游离药物。
  • 基于HapImmune的双特异性T细胞衔接器在索托拉西布处理下选择性且强效杀伤索托拉西布耐药肺癌细胞。
  • 该衔接器对具有不同HLA超型HLA-A*02和A*03/11的KRASG12C突变细胞有效,提示MHC限制性 loosening。

关键数值与推荐

  • 使用FDA批准的共价抑制剂索托拉西布和奥希替尼。
  • HapImmune抗体结合药物-肽 conjugate/MHC复合物但不结合游离药物。
  • 对KRASG12C突变细胞中HLA-A*02和A*03/11超型均有效。

临床怎么用

  • 原文未据此给出临床推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

UNLABELLED: Intracellular oncoproteins can be inhibited with targeted therapy, but responses are not durable. Immune therapies can be curative, but most oncogene-driven tumors are unresponsive to these agents. Fragments of intracellular oncoproteins can act as neoantigens presented by the major histocompatibility complex (MHC), but recognizing minimal differences between oncoproteins and their normal counterparts is challenging. We have established a platform technology that exploits hapten-peptide conjugates generated by covalent inhibitors to create distinct neoantigens that selectively mark cancer cells. Using the FDA-approved covalent inhibitors sotorasib and osimertinib, we developed "HapImmune" antibodies that bind to drug-peptide conjugate/MHC complexes but not to the free drugs. A HapImmune-based bispecific T-cell engager selectively and potently kills sotorasib-resistant lung cancer cells upon sotorasib treatment. Notably, it is effective against KRASG12C-mutant cells with different HLA supertypes, HLA-A*02 and A*03/11, suggesting loosening of MHC restriction. Our strategy creates targetable neoantigens by design, unifying targeted and immune therapies. SIGNIFICANCE: Targeted therapies against oncoproteins often have dramatic initial efficacy but lack durability. Immunotherapies can be curative, yet most tumors fail to respond. We developed a generalizable technology platform that exploits hapten-peptides generated by covalent inhibitors as neoantigens presented on MHC to enable engineered antibodies to selectively kill drug-resistant cancer cells. See related commentary by Cox et al., p. 19. This article is highlighted in the In This Issue feature, p. 1.

来源:Cancer Discov,查看原文。版权归原作者所有。

引用

  1. Hattori T, Maso L, Araki KY, et al. Creating MHC-Restricted Neoantigens with Covalent Inhibitors That Can Be Targeted by Immune Therapy. Cancer Discov. 2023. PMID: 36250888. doi:10.1158/2159-8290.CD-22-1074

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。